Zhi Tong Cai Jing·2025-12-14 12:23Major Events - Fuhong Hanlin (02696) has received acceptance for the listing registration application of Hanshu® combined chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer, which has been included in priority review [1] - Biyuan (00926) increases investment in ERX, maintaining a 3% stake to support the innovative research and development of non-GLP-1 weight loss therapies [1] - CSPC Pharmaceutical Group (01093) has received approval for a new indication for Donyi® (Irinotecan Liposome Injection) [1] - COSCO Shipping Energy (01138) has signed shipbuilding contracts for one ethylene ship and eighteen oil tankers, with a total cost of 7.882 billion yuan [1] - Innovent Biologics (09969) has achieved positive results in the Phase IIb clinical trial of Obinutuzumab for systemic lupus erythematosus and has initiated the Phase III clinical trial [1] - Delin Holdings (01709) is deploying efficient mining hardware at selected overseas mines to actively develop and expand institutional-level Bitcoin mining operations [1] - Fenbi (02469) has signed a strategic cooperation agreement with Huatu to consolidate both parties' leadership positions in the industry [1] Operating Performance - R&F Properties (02777) reported total sales revenue of approximately 12.7 billion yuan in the first 11 months, representing a year-on-year increase of 24.63% [1] - ZhongAn Online (06060) reported total original insurance premium income of approximately 32.904 billion yuan in the first 11 months [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 97.218 billion yuan in the first 11 months [1] - China Resources Land (01109) reported a cumulative contract sales amount of approximately 192.6 billion yuan in the first 11 months, a year-on-year decrease of 15.9% [1]